Imugene Limited Stock Performance
| IUGNF Stock | USD 0.22 0.01 4.35% |
The company retains a Market Volatility (i.e., Beta) of 0.22, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Imugene's returns are expected to increase less than the market. However, during the bear market, the loss of holding Imugene is expected to be smaller as well. At this point, Imugene Limited has a negative expected return of -0.27%. Please make sure to check out Imugene's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Imugene Limited performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Imugene Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 29.5 M | |
| Total Cashflows From Investing Activities | -221 K |
Imugene |
Imugene Relative Risk vs. Return Landscape
If you would invest 78.00 in Imugene Limited on April 25, 2025 and sell it today you would lose (55.00) from holding Imugene Limited or give up 70.51% of portfolio value over 90 days. Imugene Limited is currently producing negative expected returns and takes up 19.1844% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Imugene, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Imugene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Imugene's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Imugene Limited, and traders can use it to determine the average amount a Imugene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0139
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IUGNF |
Estimated Market Risk
| 19.18 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Imugene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Imugene by adding Imugene to a well-diversified portfolio.
Imugene Fundamentals Growth
Imugene Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Imugene, and Imugene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Imugene Pink Sheet performance.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 737.79 M | |||
| Shares Outstanding | 6.42 B | |||
| Price To Book | 8.51 X | |||
| Price To Sales | 61.84 X | |||
| Revenue | 12.97 M | |||
| EBITDA | (37.56 M) | |||
| Cash And Equivalents | 99.89 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 673.43 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (30.85 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 147.61 M | |||
About Imugene Performance
By analyzing Imugene's fundamental ratios, stakeholders can gain valuable insights into Imugene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Imugene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Imugene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Imugene is traded on OTC Exchange in the United States.Things to note about Imugene Limited performance evaluation
Checking the ongoing alerts about Imugene for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Imugene Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Imugene Limited generated a negative expected return over the last 90 days | |
| Imugene Limited has high historical volatility and very poor performance | |
| Imugene Limited has some characteristics of a very speculative penny stock | |
| Imugene Limited has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.97 M. Net Loss for the year was (37.87 M) with profit before overhead, payroll, taxes, and interest of 12.97 M. | |
| Imugene Limited has accumulated about 99.89 M in cash with (30.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 15.0% of the company shares are held by company insiders |
- Analyzing Imugene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Imugene's stock is overvalued or undervalued compared to its peers.
- Examining Imugene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Imugene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Imugene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Imugene's pink sheet. These opinions can provide insight into Imugene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Imugene Pink Sheet analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |